Enk A H, Knop J
Universitäts-Hautklinik Mainz.
Hautarzt. 1998 Oct;49(10):774-6. doi: 10.1007/s001050050824.
High dose intravenous immunoglobulins (IVIG) have been shown to be effective in different autoimmune diseases. We report on the use of IVIG in patients with pemphigus vulgaris (PV) or pemphigus foliaceus (PF) resistant to conventional therapy. Six patients who presented with a relapse of their disease following conventional immunosuppressive treatment with prednisolone and azathioprine were additionally treated with 2 g/kg of IVIG every four weeks. Six to nine cycles of this therapy were given to each patient. All patients showed healing of their blisters without evidence of relapse even when steroids and immunosuppressants were tapered. None of the patients relapsed within one year of follow-up, although IVIG treatment was discontinued. Side effects of IVIG treatment were moderate with only slight evidence of headaches. We suggest that adjuvant treatment of PV and PF resistant to conventional immunosuppressive strategies is a useful addition to our therapeutic arsenal in both diseases.
高剂量静脉注射免疫球蛋白（IVIG）已被证明在不同的自身免疫性疾病中有效。我们报告了IVIG在对传统治疗耐药的寻常型天疱疮（PV）或落叶型天疱疮（PF）患者中的应用。6例在接受泼尼松龙和硫唑嘌呤传统免疫抑制治疗后疾病复发的患者，每4周额外接受2 g/kg的IVIG治疗。每位患者接受6至9个周期的该治疗。所有患者的水疱均愈合，即使在逐渐减少类固醇和免疫抑制剂用量时也无复发迹象。尽管停止了IVIG治疗，但所有患者在随访的一年内均未复发。IVIG治疗的副作用较轻，仅有轻微头痛迹象。我们认为，对于对传统免疫抑制策略耐药的PV和PF，辅助治疗是这两种疾病治疗手段的有益补充。
